CD274 and neoplasm: The open-label, investigator-initiated, phase 2 umbrella trial (NCT03699449) enrolled 70 patients with platinum-resistant ovarian cancer to receive combination therapy of durvalumab and olaparib based on homologous recombination deficiency (HRD) and programmed death ligand 1 (PD-L1) status determined by archival tumor sample assessment [114].